Capital Fund Management (CFM)
TEVA icon

Capital Fund Management (CFM)’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Fund Management (CFM)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.43M Sell
113,900
-19,900
-15% -$640K 0.02% 1090
2025
Q4 		$4.18M Sell
133,800
-10,200
-7% -$251K 0.01% 1283
2025
Q3 		$2.91M Sell
144,000
-256,900
-64% -$4.51M 0.01% 1578
2025
Q2 		$6.72M Buy
400,900
+246,500
+160% +$3.98M 0.02% 969
2025
Q1 		$2.37M Sell
154,400
-62,600
-29% -$1.12M 0.01% 1347
2024
Q4 		$4.78M Sell
217,000
-110,100
-34% -$2M 0.01% 1106
2024
Q3 		$5.89M Sell
327,100
-182,600
-36% -$3.2M 0.02% 950
2024
Q2 		$8.28M Buy
509,700
+134,400
+36% +$2.07M 0.02% 757
2024
Q1 		$5.3M Buy
375,300
+103,800
+38% +$1.31M 0.02% 1024
2023
Q4 		$2.83M Buy
+271,500
New +$2.53M 0.01% 1363
2019
Q2 		– Sell
-322,300
Closed -$5.05M – 1913
2019
Q1 		$5.05M Sell
322,300
-658,800
-67% -$11.6M 0.05% 495
2018
Q4 		$15.1M Sell
981,100
-570,400
-37% -$11.7M 0.13% 200
2018
Q3 		$33.4M Buy
1,551,500
+59,000
+4% +$1.37M 0.18% 136
2018
Q2 		$36.3M Buy
1,492,500
+457,900
+44% +$9.34M 0.19% 150
2018
Q1 		$17.7M Sell
1,034,600
-183,200
-15% -$3.58M 0.11% 279
2017
Q4 		$23.1M Buy
1,217,800
+249,900
+26% +$3.76M 0.13% 203
2017
Q3 		$17M Buy
967,900
+231,600
+31% +$5.21M 0.12% 211
2017
Q2 		$24.5M Sell
736,300
-300,800
-29% -$9.31M 0.2% 145
2017
Q1 		$33.3M Buy
1,037,100
+361,100
+53% +$12.3M 0.28% 98
2016
Q4 		$24.5M Buy
676,000
+632,900
+1,468% +$25.3M 0.21% 129
2016
Q3 		$1.98M Buy
43,100
+33,400
+344% +$1.74M 0.02% 766
2016
Q2 		$487K Buy
+9,700
New +$516K ﹤0.01% 1185
2016
Q1 		– Sell
-105,200
Closed -$6.91M – 1830
2015
Q4 		$6.91M Buy
105,200
+68,500
+187% +$4.23M 0.07% 366
2015
Q3 		$2.07M Sell
36,700
-60,800
-62% -$3.94M 0.02% 607
2015
Q2 		$5.76M Buy
97,500
+46,700
+92% +$2.88M 0.07% 356
2015
Q1 		$3.17M Sell
50,800
-186,200
-79% -$10.8M 0.04% 464
2014
Q4 		$13.6M Sell
237,000
-20,900
-8% -$1.16M 0.16% 164
2014
Q3 		$13.9M Sell
257,900
-168,800
-40% -$8.94M 0.16% 153
2014
Q2 		$22.4M Sell
426,700
-45,100
-10% -$2.31M 0.24% 105
2014
Q1 		$24.9M Buy
471,800
+461,900
+4,666% +$21.3M 0.31% 53
2013
Q4 		$397K Sell
9,900
-17,100
-63% -$673K ﹤0.01% 1343
2013
Q3 		$1.02M Buy
27,000
+3,200
+13% +$125K 0.01% 867
2013
Q2 		$933K Buy
+23,800
New +$927K 0.01% 820

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Fund Management (CFM)'s TEVA Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 114,656 shares — an estimated $2.01M sold.

Capital Fund Management (CFM) first reported a position in TEVA in Q2 2013 and held it in 25 quarters. The position peaked at $52.3M in Q3 2016. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Capital Fund Management (CFM) reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 114,656 Teva Pharmaceuticals shares in Q3 2025, an estimated $2.01M.
  • Capital Fund Management (CFM) first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • Capital Fund Management (CFM)'s Teva Pharmaceuticals position peaked at $52.3M in Q3 2016.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.